Mesoblast CMO reports initial share and option stakes
Mesoblast Ltd director and Chief Medical Officer Eric Allen Rose has filed an initial Form 3 detailing his equity interests in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mesoblast Ltd director and Chief Medical Officer Eric Allen Rose has filed an initial Form 3 detailing his equity interests in the company. He directly holds 6,034,554 Ordinary Shares and an additional 714,720 Ordinary Shares, which are represented by American Depositary Shares.
He also reports multiple option awards over Ordinary Shares, including 820,000 underlying shares at an exercise price of $2.46 per share expiring in 2032, and other grants at exercise prices of $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031. Several recent option grants vest only if Mr. Rose achieves specified milestones.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (4)
- F1. Such Ordinary Shares are represented by American Depositary Shares.
- F2. Granted on October 16, 2023. Vesting is dependent on Mr. Rose achieving certain milestones.
- F3. Granted on August 27, 2024. Vesting is dependent on Mr. Rose achieving certain milestones.
- F4. Granted on August 26, 2025. Vesting is dependent on Mr. Rose achieving certain milestones.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Mesoblast (MEOBF) Form 3 for Eric Allen Rose show?
What stock options are reported for Eric Allen Rose in the Mesoblast Form 3?
Do Eric Allen Rose’s Mesoblast options depend on performance milestones?
Does this Mesoblast Form 3 indicate recent buying or selling by Eric Allen Rose?
How long do Eric Allen Rose’s Mesoblast options remain exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.
